Opinion|Videos|December 11, 2024
Hyperkalemia and Heart Failure Insights
Author(s)Orly Vardeny, PharmD, MS
A panelist discusses how the FINEARTS-HF trial employed rigorous potassium-monitoring protocols and predefined hyperkalemia thresholds to evaluate finerenone's safety profile in patients with heart failure (HF), revealing important associations between baseline characteristics and hyperkalemia risk while demonstrating the drug's complex effects on potassium homeostasis.
Advertisement
Video content above is prompted by the following:
- What methodological considerations and unique insights emerged from the FINEARTS-HF trial's investigation of hyperkalemia risk, and how did the study design address the relationship between potassium levels and clinical outcomes?
- What baseline characteristics were associated with a higher risk of developing hyperkalemia in the FINEARTS-HF trial, and how might these findings inform the management of patients with HF?
- How did the impact of finerenone on potassium levels and hyperkalemia-related outco-mes differ from placebo, and what are the implications for its clinical use in patients with heart failure?
Advertisement
Related to this article
An analysis finds distinct adverse event reporting patterns across immunosuppressive regimens, highlighting the need for tailored safety monitoring.
Sjögren disease involves far more than dry eyes and mouth, and variable symptoms plus multispecialty testing delay diagnosis, says Steven Carsons, MD.
Early MASH risk stratification, drug choice, and aligned coverage could improve outcomes, explained Zobair Younossi, MD.
These phase 3 EXCALIBER-RRMM findings build on earlier MRD-negative complete response results supporting FDA approval of the iberdomide-based regimen.
Admilparant 60 mg met the ALOFT-IPF primary end point, significantly improving FVC change vs placebo at 52 weeks in idiopathic pulmonary fibrosis.
At a roundtable in Cleveland, kidney experts said IgA nephropathy and FSGS often go unrecognized, calling for EHR flags and better referral channels.
AI quantitative CT (UCLA QILD, Brainomix e-Lung) predicts FVC decline and drug response in PPF, strengthening biomarkers beyond spirometry in INBUILD.
The conference session featured updates on several clinical trials, including the BRUNELLO trial, for treatment of diabetic macular edema (DME).
Advertisement
Advertisement
Trending on AJMC
1
ACA Subsidies End for 189,000 Duplicate or Deceased Enrollees
2
5 Things to Know About the One Big Beautiful Bill Act
3
Coroner Reports Pennsylvania's Sixth Measles-Associated Death
4
FAQ: How Payers Can Close HIV Prevention and PrEP Access Gaps
5